Wnt pathway agonist acting via inhibition of Dkk1 with no GSK-3β inhibition. TCF-Luciferase EC50=0.63µM. WAY262611 was able to enhance trabecular bone formation rate in the tibia of OVX rats following oral administration.
Product Details
| Alternative Name: | (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine |
| |
| Formula: | C20H22N4 |
| |
| MW: | 318.4 |
| |
| CAS: | 123231-07-1 |
| |
| Purity: | ≥97% (TLC) |
| |
| Appearance: | Off-white solid. |
| |
| Solubility: | Soluble in DMSO (30mg/ml) or in 100% ethanol (25mg/ml). |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
| |
| Handling: | Solutions can be stored at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
(1-(4-Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: A wingless b-Catenin Agonist That Increases Bone Formation Rate: J. Pelletier, et al.; J. Med. Chem.
52, 6962 (2009),
Abstract;
